Amit Suman

Amit Suman

Active Director Director DIN 05251408
DIN 05251408 First appointment Mar 2012 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2012
Shareholding value •••• Premium profile

About Amit Suman

Data last updated:

Amit Suman is a Director at Archem Drugs Private Limited (since 2012). The company operates in Pharma. Archem Drugs Private Limited reported revenue of ₹58.8 Lakh (FY 2025).

DIN 05251408
Primary Designation Director
Industry Pharma
First Appointment 30 Mar 2012
Oldest Company Age 39 yrs
Largest company Archem Drugs Private Limited · ₹58.8 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Archem Drugs Private Limited U24230BR1986PTC002468
Director30 Mar 20121986₹58.8 Lakh (FY 2025)Active

Board colleagues of Amit Suman

NameDINCompanyDesignation
Satyendra Kumar00746002Archem Drugs Private LimitedDirector

Directorship timeline

Open interactive timeline →
Archem Drugs Private Limited
Premium access

Shareholding and investment profile for Amit Suman

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Amit Suman

Amit Suman currently holds 1 directorship: Archem Drugs Private Limited (Director, since 30 Mar 2012, revenue ₹58.8 Lakh (FY 2025)).

Amit Suman was first appointed on 30 Mar 2012 as Director at Archem Drugs Private Limited.

The current boards of Amit Suman's companies include Satyendra Kumar (Archem Drugs Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available